Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for

ZUG, Switzerland, March 18, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor...

Related Keywords

United States ,Thailand ,United Kingdom ,Israel ,Bangkok ,Krung Thep Mahanakhon ,Canada ,Russia ,Switzerland ,Ukraine ,Maryann Cimino ,Marca Riedl ,Exchange Commission ,University Of California San Diego ,European Union ,Angioedema Center ,Clinical Service ,Us Hereditary Angioedema Association ,Regional Conference ,Treating Hereditary Angioedema Attacks ,Clinical Director ,Angioedema Association ,California San Diego ,Clinical Service Chief ,Statement Regarding Forward Looking ,Annual Report ,Nasdaq Phvs ,Pharvarisnv ,